Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30790721 | 0.79 | CYP17A1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30790732 | 0.77 | SUV39H2 (0.40) | HRH4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL30790709 | 0.74 | HRH3 (0.50) | — | |
| SCHEMBL31383394 | 0.71 | CYP2C19 (0.58) | HRH4 | |
| SCHEMBL230404 | 0.71 | HTR3E (0.53) | HRH4 | |
| SCHEMBL9499780 | 0.71 | ALDH1A1 (0.52) | — | |
| SCHEMBL23902364 | 0.70 | APP (0.41) | HRH4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21374330 | 0.70 | APP (0.41) | HRH4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20609148 | 0.70 | APP (0.41) | HRH4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20609147 | 0.70 | APP (0.41) | HRH4PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| EP-4581032-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED Limited (CN) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024046457-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED LIMITED (CN) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | CBR1, CNR1, CBR3 | HRH4 96/4885PSEN1 2649/4885PSEN2 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.